Pozanicline

Pozanicline (INN,^[1] codenamed ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects.^[2][3][4] Animal studies suggested it useful for the treatment of ADHD^[5] and subsequent human trials have shown ABT-089 to be effective for this application.^[6] It binds with high affinity subtype-selective to the α₄β₂ nicotinic acetylcholine receptors and has partial agonism to the α₆β₂ subtype,^[7][8] but not the α₇ and α₃β₄ subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class.^[9][10]

Pozanicline

Identifiers
IUPAC name 2-Methyl-3-{[(2S)-pyrrolidin-2-yl]methoxy}pyridine
CAS Number	161417-03-4 Y
PubChem CID	178052
ChemSpider	155000 N
UNII	CL2002R563
CompTox Dashboard (EPA)	DTXSID20167149
Chemical and physical data
Formula	C11H16N2O
Molar mass	192.262 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC=N1)OC[C@@H]2CCCN2
InChI InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1 N Key:YRVIKLBSVVNSHF-JTQLQIEISA-N N
NY (what is this?)  (verify)

Synthesis

Pozanicline is synthesized from 2-methyl-3-hydroxypyridine and Boc-L-Prolinol through a dehydration reaction followed by deprotection of the nitrogen atom of prolinol^[11]